Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
+4.01%
-0.22%
-3.24%
+0.67%
ABBV
AbbVie
$189.26
Chart
$186.98 (+1.22%)
$172.99 (+9.41%)
$210.75 (-10.20%)
$181.94 (+4.02%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
+4.01%
-0.22%
-3.24%
+0.67%
ABBV
AbbVie
Current Price
$189.26
Buy
Login to view AbbVie (ABBV) recommendation from the last 90 days from financial news and social media.
Chart
$186.98 (+1.22%)
$172.99 (+9.41%)
$210.75 (-10.20%)
$181.94 (+4.02%)
ABBV Latest Analysis
Dementia Associated with Alzheimers Disease Drug Development Surges with 180 Companies Pushing New Therapeutic Frontiers | DelveInsight. Dementia Associated with Alzheimer'.s Disease Drug Development Surges with 180 Companies Pushing New Therapeutic Frontiers |. DelveInsightDementia associated with Alzheimer'.s disease is a progressive neurodegenerative condition characterized by memory loss cognitive decline and impaired daily functioning. The growing aging population worldwide is l
Thu Jul 17, 2025
AbbVie (ABBV) Surpasses Market Returns: Some Facts Worth Knowing. The latest trading day saw AbbVie (ABBV) settling at $190.58 representing a 2.25% change from its previous close.
Wed Jul 16, 2025
Looking Into AbbVies Recent Short Interest. ) short percent of float has risen 8.43% since its last report. The company recently reported that it has Short interest is the number of shares that have been sold short but have not yet been covered or closed out. is when a trader sells shares of a company they do not own with the hope that the price will fall. Traders make money from short selling if the price ...
Wed Jul 16, 2025
Heres How to Play AbbVie Stock as it Reaches Golden Cross . ABBV hits a ish golden cross as Skyrizi and Rinvoq drive growth offsetting Humira losses and aesthetic headwinds.
Tue Jul 15, 2025
Waldenstrom Macroglobulinemia Market Sees Surging Demand Across the 7MM Amid BTK Inhibitor Advancements | DelveInsight. Waldenstrom Macroglobulinemia Market Sees Surging Demand Across the 7MM Amid BTK Inhibitor Advancements |. DelveInsight The Waldenstrom macroglobulinemia market is witnessing steady growth driven by advances in targeted therapies particularly BTK inhibitors like IMBRUVICA and BRUKINSA. Rising awareness improved diagnostic techniques and increasing clinical trial activity ar
Mon Jul 14, 2025
Ex-Dividend Reminder: Buckle AbbVie and PNC Financial Services Group. Looking at the universe of stocks we cover at Dividend Channel on 7/15/25 Buckle Inc. (Symbol: BKE) AbbVie Inc (Symbol: ABBV) and PNC Financial Services Group (Symbol: PNC) will all trade ex-dividend for their respective upcoming dividends. Buckle Inc. will pay its quarter
Fri Jul 11, 2025
Boeing Joby Aviation Oracle And A Health Care Stock: CNBCs Final Trades. The investment landscape is shifting as companies across various sectors demonstrate resilience and innovation prompting investors to reassess their portfolios.On CNBC'.s “.Halftime Report Final Trades”. ) can break above $197 it marches towards .According to recent news IGI Therapeutics SA a wholly owned subsidiary of Ichnos Glenmark Innovation Inc. and AbbVie announced on Thursday an exclusive licensing agre
Fri Jul 11, 2025
Glenmark Pharma shares rally 14% on AbbVie boost. analysts hike targets to Rs 2800 . Glenmark Pharma surged 14% after its subsidiary signed a $700 million licensing deal with AbbVie for its experimental cancer drug ISB 2001. Analysts see up to 29% more upside with technical experts advising a buy on dips strategy. The stock broke out from a key gap zone and brokerages like Motilal Oswal see targets up to Rs 2800.
Fri Jul 11, 2025
Why Is AbbVie Stock Trading Higher On Thursday?. ) on Thursday announced an exclusive licensing agreement for IGI’.s lead investigational asset ISB 2001 developed using IGI’.s proprietary BEAT protein platform for .“.Multispecifics including trispecific antibodies represent a new frontier in immuno-oncology with the potential to deliver deeper more durable responses by engaging multiple targets simultaneously”. said AbbVie will receive exclusive rights to develop manufacture
Thu Jul 10, 2025
Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001 a First-in-Class CD38×BCMA×CD3 Trispecific Antibody. ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM) NEW YORK and NORTH CHICAGO Ill. July 10 2025 /PRNewswire/ -- IGI Therapeutics SA a wholly owned subsidiary of New York-based Ichnos Glenmark Innovation Inc. (IGI) and...
Thu Jul 10, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
ABBV Stock trends
ABBV Stock performance
ABBV Stock analysis
ABBV investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings